About Bio-Reference Laboratories (NASDAQ:BRLI)
Bio-Reference Laboratories, Inc. is a clinical testing laboratory, which offers testing, information and related services to physician offices, clinics, hospitals, employers and governmental units. The Company offers a range of laboratory testing services utilized by healthcare providers in the detection, diagnosis, evaluation, monitoring and treatment of diseases. It is focused on esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health and correctional health care. It offers a list of chemical diagnostic tests, including blood and urine analysis, blood chemistry, hematology services, serology, radio-immuno analysis, toxicology and other tissue analysis. It operates a clinical knowledge management service through its PSIMedica business unit. It also operates a Web-based connectivity portal solution for laboratories and physicians through its CareEvolve subsidiary. Its laboratory testing business consists of routine testing and esoteric testing.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Medical Laboratories & Research
- Sub-Industry: Health Care Services
- Symbol: NASDAQ:BRLI
- CUSIP: 09057G60
- Web: N/A
- 50 Day Moving Avg: $41.81
- 200 Day Moving Avg: $36.97
- 52 Week Range: $26.32 - $47.49
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 14.98
- P/E Growth: 0.00
- Average Volume: 653,202 shs.
Frequently Asked Questions for Bio-Reference Laboratories (NASDAQ:BRLI)
What is Bio-Reference Laboratories' stock symbol?
Bio-Reference Laboratories trades on the NASDAQ under the ticker symbol "BRLI."
How were Bio-Reference Laboratories' earnings last quarter?
Bio-Reference Laboratories Inc (NASDAQ:BRLI) released its quarterly earnings data on Thursday, December, 18th. The company reported $0.66 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.63 by $0.03. The firm earned $227.60 million during the quarter, compared to analysts' expectations of $228.81 million. Bio-Reference Laboratories's revenue was up 18.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.40 EPS. View Bio-Reference Laboratories' Earnings History.
Who are some of Bio-Reference Laboratories' key competitors?
Some companies that are related to Bio-Reference Laboratories include Thermo Fisher Scientific (TMO), Quintiles IMS Holdings (Q), Agilent Technologies (A), Quest Diagnostics (DGX), Laboratory Corp. of America Holdings (LH), PerkinElmer (PKI), Bio-Rad Laboratories (BIO), DexCom (DXCM), Icon Plc (ICLR), PRA Health Sciences (PRAH), VWR Corp (VWR), Charles River Laboratories Intl. (CRL), Bruker (BRKR), Alere (ALR), PAREXEL International (PRXL), EXACT Sciences (EXAS), WuXi PharmaTech (Cayman) (WX) and Accelerate Diagnostics (AXDX).
How do I buy Bio-Reference Laboratories stock?
Shares of Bio-Reference Laboratories can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Bio-Reference Laboratories stock cost?
One share of Bio-Reference Laboratories stock can currently be purchased for approximately $34.61.
Consensus Ratings for Bio-Reference Laboratories (NASDAQ:BRLI) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Bio-Reference Laboratories (NASDAQ:BRLI)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Bio-Reference Laboratories (NASDAQ:BRLI)Earnings History by Quarter for Bio-Reference Laboratories (NASDAQ:BRLI)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|6/8/2015||Q215||$0.46||$0.38||$227.33 million||$224.00 million||View||Listen|
|3/5/2015||Q115||$0.36||$0.24||$216.40 million||$209.00 million||View||Listen|
|12/18/2014||Q414||$0.63||$0.66||$228.81 million||$227.60 million||View||Listen|
|8/27/2014||Q314||$0.53||$0.55||$210.44 million||$222.10 million||View||Listen|
|6/5/2014||Q214||$0.32||$0.37||$0.20 million||$201.30 million||View||Listen|
|3/4/2014||Q114||$0.14||$0.11||$175.52 million||$181.30 million||View||Listen|
|12/19/2013||Q4||$0.40||$0.40||$188.96 million||$192.20 million||View||Listen|
|8/29/2013||Q3 2013||$0.51||$0.53||$183.50 million||$185.40 million||View||Listen|
|6/6/2013||Q2 2013||$0.41||$0.41||$176.04 million||$176.50 million||View||Listen|
|2/28/2013||Q1 2013||$0.28||$0.31||$165.44 million||$161.30 million||View||Listen|
|8/30/2012||Q312||$0.43||$0.45||$0.17 million||$0.17 million||View||N/A|
|12/16/2010||$0.30||$0.31||$124.19 million||$126.60 million||View||N/A|
Earnings Estimates for Bio-Reference Laboratories (NASDAQ:BRLI)
Current Year EPS Consensus Estimate: $1.98 EPS
Next Year EPS Consensus Estimate: $2.31 EPS
Dividend History for Bio-Reference Laboratories (NASDAQ:BRLI)
No dividend announcements for this company have been tracked by MarketBeat.com
Headline Trends for Bio-Reference Laboratories (NASDAQ:BRLI)
Latest Headlines for Bio-Reference Laboratories (NASDAQ:BRLI)
Bio-Reference Laboratories (BRLI) Chart for Tuesday, May, 23, 2017